Ragini Kudchadkar, MD

Ragini Kudchadkar, MD, discusses future research directions for patients with rare, non-melanoma skin cancers.

Ragini Kudchadkar, MD, discusses the durability of immunotherapy in non-melanoma skin cancers.

Ragini Kudchadkar, MD, assistant professor, Department of Hematology and Medical Oncology, associate director, Hematology and Medical Oncology Fellowship Program-Clinical/Service, Emory University School of Medicine, discusses immunotherapy in Merkel cell carcinoma.

Ragini Kudchadkar, MD, assistant professor, Department of Hematology and Medical Oncology, associate director, Hematology and Medical Oncology Fellowship Program-Clinical/Service, Emory University School of Medicine, discusses the FDA approval of avelumab for the treatment of patients with Merkel cell carcinoma.

Ragini Kudchadkar, MD, assistant professor, medical oncology, Moffitt Cancer Center, discusses the potential for combining therapies for the treatment of melanoma.

Ragini Kudchadkar, MD, assistant professor, medical oncology, Moffitt Cancer Center, discusses testing for melanoma.

Ragini Kudchadkar, MD, assistant professor, medical oncology, Moffitt Cancer Center, discusses the benefits of combining BRAF and MEK inhibitors when treating melanoma.